Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage?

Eye

Volumn 23, Issue 8, 2009, Pages 1698-1701

  Romano, M R ^a   Gibran, S K ^b   Marticorena, J ^a   Wong, D ^a,c   Heimann, H ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Preoperative bevacizumab injection; Proliferative diabetic retinopathy; Vitreous haemorrhage

Indexed keywords

BEVACIZUMAB;

ADULT; ARTICLE; CATARACT; CATARACT EXTRACTION; CILIARY DISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DIABETIC VITREOUS HEMORRHAGE; FEMALE; FOLLOW UP; HUMAN; MALE; MEDICAL SPECIALIST; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PREOPERATIVE PERIOD; RECURRENT DISEASE; SLIT LAMP; VISUAL ACUITY; VITRECTOMY; VITREOUS HEMORRHAGE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CATARACT; DIABETIC RETINOPATHY; FEMALE; HUMANS; INCIDENCE; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PILOT PROJECTS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RECURRENCE; VISUAL ACUITY; VITRECTOMY; VITREOUS HEMORRHAGE;

EID: 69049096319     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2008.354     Document Type: Article

References (12)

1. Novak MA, Rice TA, Michels RG, Auer C. Vitreous hemorrhage after vitrectomy for diabetic retinopathy. Ophthalmology 1984; 91: 1485-1489. (Pubitemid 15197020)
2. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 1695.e1-1695.e15. (Pubitemid 44442453)
3. Landers MB, Perraki AD. Management of post-vitrectomy persistent vitreous hemorrhage in pseudophakic eyes. Am J Ophthalmol 2003; 136: 989-993.
4. Yang CM, Yeh PT, Yang CH. Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology 2007; 114: 710-715.
5. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487.
6. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006; 26: 275-278. (Pubitemid 44318179)
7. Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 2008; 246: 837-842.
8. Yang CM, Yeh PT, Yang CH, Chen MS. Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy. Am J Ophthalmol 2008; 146: 211-217.
9. West JF, Gregor ZJ. Fibrovascular ingrowth and recurrent haemorrhage following diabetic vitrectomy. Br J Ophthalmol 2000; 84: 822-825.
10. Comer GM, Ciulla TA. Pharmacotherapy for diabetic retinopathy. Curr Opin Ophthalmol 2008; 15: 508-518.
11. Warner T. Relationships between the endothelin and nitric oxide pathways. Clin Exp Pharmacol Physiol 1999; 26: 247-252. (Pubitemid 29128024)
12. Kent D, Sheridan C. Choroidal neovascularization: a wound healing perspective. Mol Vis 2003; 9: 747-755. (Pubitemid 38097640)